About Singapore factory
AbbVie’s Singapore facility, located in Singapore’s Tuas Biomedical Park, is a small molecule and biologics manufacturing facility serving markets around the world. This new investment will add 24,000 liters of biologic drug substance production capacity to AbbVie’s global manufacturing network, supporting current products as well as new immunology and oncology compounds in AbbVie’s pipeline. It will be.
“This expansion announcement is one of many investments in AbbVie’s Singapore-based operations and represents a proud continuation of our 10-year partnership with the Singapore government.” said Dr. Ajita Saleki Gerhardt, Vice President and Chief. Operations officer. “The expansion of our Singapore site strengthens our global manufacturing capabilities, supports our growing biologics pipeline, and enables AbbVie to continue delivering on its commitment to patients now and in the future. Become.”
With this announcement, AbbVie has invested more than $740 million in the acquisition, modernization and expansion of its Singapore facilities over the past decade. Once fully operational, AbbVie’s expanded Singapore manufacturing facility, AbbVie’s only manufacturing site in Asia, will employ more than 500 employees in manufacturing, quality assurance, supply chain, engineering, and management roles. .
“We are pleased that AbbVie has chosen to expand its biopharmaceutical manufacturing capacity in Singapore for current and future innovative medicines. We are grateful for their continued confidence in our strength. AbbVie’s investment will strengthen Singapore’s cutting-edge manufacturing ecosystem and create exciting job opportunities here.” said Cindy Ko, executive vice president of the association.
Expansion work is expected to begin later this year, with operations expected to begin in 2026. AbbVie’s Singapore manufacturing facility is part of AbbVie’s operations team, which is comprised of 14,000 employees working in more than 30 manufacturing, operations and distribution locations across the United States. , Asia, Europe, Puerto Rico, and South America.
See more AbbVie news
AbbVie recently entered into a definitive agreement with Cerevel Therapeutics to acquire its neuroscience pipeline of multiple clinical-stage and preclinical candidates with potential across schizophrenia, Parkinson’s disease (PD), and mood disorders.